Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis | Zendy

Tadashi Terui | Zendy; Satomi Kobayashi | Zendy; Yukari Okubo | Zendy; Masamoto Murakami | Zendy; Richuan Zheng | Zendy; Hitomi Morishima | Zendy; Ryosuke Goto | Zendy; Takayuki Kimura | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis

Author(s) -

Tadashi Terui,

Satomi Kobayashi,

Yukari Okubo,

Masamoto Murakami,

Richuan Zheng,

Hitomi Morishima,

Ryosuke Goto,

Takayuki Kimura

Publication year - 2019

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2019.1394

Subject(s) - medicine , palmoplantar pustulosis , placebo , randomized controlled trial , dermatology life quality index , refractory (planetary science) , gastroenterology , surgery , dermatology , psoriasis , pathology , disease , alternative medicine , physics , astrobiology

Palmoplantar pustulosis (PPP) causes erythematous, scaly plaques with recurrent sterile pustules refractory to treatment and with few randomized clinical trials conducted. Evidence points to involvement of interleukin 23 in the pathogenesis of PPP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research